Kura

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Retrieved on: 
Wednesday, March 6, 2024
NSCLC, SAN, FTI, Lung cancer, Safety, Pharmacokinetics, KURA, Kura, TKI, Cancer, Pharmaceutical industry

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial.

Key Points: 
  • “Dosing of the first patient in combination in our Phase 1 trial of KO-2806 marks a significant milestone for our next-generation FTI program,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Concurrent with the monotherapy dose escalation, Kura is evaluating KO-2806 in dose-escalation combination cohorts with other targeted therapies, beginning with cabozantinib in ccRCC.
  • The Company expects to begin dosing in combination with adagrasib in KRASG12C-mutant non-small cell lung cancer (NSCLC) next quarter.
  • For more information regarding FIT-001, please visit www.clinicaltrials.gov (identifier: NCT06026410 ).

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Retrieved on: 
Monday, February 26, 2024
AML, Azacitidine, Menin, KMT2A, Safety, Prognosis, FLT3, Pharmacokinetics, Venetoclax, Patient, KURA, Kura, Acute myeloid leukemia, LDAC, Cancer, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

Key Points: 
  • “Roughly half of patients with relapsed or refractory NPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is particularly poor,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Trial participants will be enrolled in one of five dose escalation cohorts, including a cohort of NPM1-mutant AML patients with a documented FLT3 co-mutation, who will be treated in combination with the FLT3 inhibitor gilteritinib.
  • Kura is conducting a series of studies to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations.
  • Preclinical data for menin inhibitors in combination with multiple FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone.

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, January 30, 2024
KURA, Failure, Acute myeloid leukemia, Venetoclax, Research, Division, MHS, Patient, Safety, QT interval, AML, Bone marrow, MBBS, QD, Yale Cancer Center, Disease, Therapy, Postcholecystectomy syndrome, Risk, ID, Cancer, Kura, Pharmaceutical industry

Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.

Key Points: 
  • Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.
  • The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was 53% (8/15).
  • As of the data cutoff, 80% (16/20) of patients remain on trial, including 100% (11/11) of all NPM1-m patients.
  • “We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Kura Oncology Announces Oversubscribed $150 Million Private Placement

Retrieved on: 
Wednesday, January 24, 2024
Research, SVB Securities, Prospectus, Cancer, Sale, Investment, Kura, Exercise, KURA, Security (finance)

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 shares of its common stock at a price of $17.25 per share, representing a premium of approximately 29% to Kura’s closing price on January 23, 2024, and pre-funded warrants to purchase 7,318,886 shares of its common stock at price per pre-funded warrant of $17.2499 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. The pre-funded warrant exercise price is $0.0001 per share. Kura anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. The private placement is expected to close on or about January 26, 2024, subject to customary closing conditions.

Key Points: 
  • Kura anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about January 26, 2024, subject to customary closing conditions.
  • Leerink Partners acted as the sole placement agent for the private placement.
  • Kura has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the pricing of the private placement.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on: 
Friday, December 8, 2023
Princess, Leukemia & Lymphoma Society, Partnership, Research, Bone marrow, KURA, Drug, Kura, SAN, Pedal, Clinical trial, Cancer, LLS, Leukemia, Patient, Acute leukemia, Pharmaceutical industry

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points: 
  • “We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
  • “Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
  • PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
  • Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

Avaya Helps UK and Ireland Enterprises Deliver AI-Powered Innovation Without Disruption

Retrieved on: 
Thursday, December 7, 2023
Telecommunications, Software, Internet, Audio, Video, Artificial Intelligence, Technology, VoIP, Security, Cloud, Pressure, PCI, Organization, Workforce, ACES, Artificial intelligence, NHS, CX, AI, Rudolf Masarek, Government, UC, Network equipment provider, Sales, Online shopping, Kura, Avaya

At the JOURNEYS with Avaya event, held in London, Avaya CEO Alan Masarek said that UK and Ireland enterprises, like their global counterparts, are increasingly turning to Avaya to help them fully realize the promise of AI within the customer experience industry.

Key Points: 
  • At the JOURNEYS with Avaya event, held in London, Avaya CEO Alan Masarek said that UK and Ireland enterprises, like their global counterparts, are increasingly turning to Avaya to help them fully realize the promise of AI within the customer experience industry.
  • According to Frost & Sullivan, in 52% of UK organizations, CX improvements are one of the main drivers for implementing AI technologies.
  • In Ireland, among other top government and private organizations, Avaya supports RelateCare, a leading provider of innovative healthcare consulting, administrative and clinical support solutions.
  • Demonstrated at JOURNEYS with Avaya was the company’s ability to deliver such innovation without disruption.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

Kura Oncology Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
European Hematology Association, Head, CRH, Cancer, Kura, ID, Acute myeloid leukemia, PI3K, Congress, AML, Investigational New Drug, Investment, Patient, KURA, EHA, HNSCC, CR, FLT3, Webcast, Toxic leukoencephalopathy, Research, FDA, Health, Safety, FTI, Disease, Pharmaceutical industry, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $28.2 million, compared to $24.3 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $11.8 million, compared to $11.1 million for the second quarter of 2022.
  • ET / 1:30 p.m. PT today, August 3, 2023, to discuss the financial results for the second quarter 2023 and to provide a corporate update.

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Sunday, June 11, 2023
Postcholecystectomy syndrome, Menin, Continuity, Venetoclax, Crystal structure, Cancer, Mutation, Massachusetts General Hospital, Kura, MEN1, Acute myeloid leukemia, Congress, Mixed-phenotype acute leukemia, AML, Dor, Patient, KURA, EHA, IDH, FLT3, SCT, CRi, Hospital, Poster, Safety, Disease, Pharmaceutical industry

The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • Notably, 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib.
  • Two patients underwent a stem cell transplant (SCT) and remain in remission as of the data cutoff, including one on post-SCT ziftomenib maintenance therapy.
  • “The clinical data presented today continue to demonstrate the ability of ziftomenib to drive durable responses as a monotherapy in heavily pretreated patients with NPM1-mutant AML.

Kura Oncology Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
KRAS, AACR, Postcholecystectomy syndrome, European Hematology Association, CRH, Cancer, Lung cancer, Kura, ID, FTI, PI3, Daunorubicin, Acute myeloid leukemia, Renal cell carcinoma, Congress, AML, Azacitidine, Dor, Investment, Patient, EGFR, KURA, EHA, CR, FLT3, Webcast, Research, Axitinib, FDA, Safety, IND, Disease, Video game, Pharmaceutical industry, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2023 were $25.2 million, compared to $20.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $11.4 million, compared to $11.9 million for the first quarter of 2022.
  • ET / 1:30 p.m. PT today, May 10, 2023, to discuss the financial results for the first quarter 2023 and to provide a corporate update.